Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma
- Author:
- No author available
- Journal Title:
- Chinese Journal of Oncology
- Issue:
- 10
- DOI:
- 10.3760/cma.j.issn.0253-3766.2012.10.015
- Key Word:
- 癌,肝细胞;复发;索拉非尼;微波消融;栓塞,治疗性;治疗效果;Carcinoma,hepatocellular;Recurrence;Sorafenib;Microwave therapentic;Embolization,therapeutic;Treatment outcome
Abstract： Objective To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer.Methods From January 2006 to January 2010,90 patients with recurrent hepatocellular carcinoma (HCC) were treated with MCT and TACE in our hospital.The treatment group received sorafenib + MCT + TACE,and the control group received MCT + TACE.Results RR of the treatment group was 66.7％,which of the control group was 52.0％ (P ＞0.05).DCR was 83.3％ in the treatment group and 64.5％ in the control group (P ＜0.05).Through a comparison of survival curves along with the extension of time,the survival rates of the two groups were decreased,but the treatment group (group 1) had a significantly higher one than the control group (group 2),with a statistically significant difference (P ＜ 0.05).Conclusion Sorafenib combined with MCT and TACE can improve the disease control rate and prolong the survival in patients with recurrent HCC.
- [1]于志坚,蔡炜,袁洪新,等.索拉非尼对不同类型原发性肝癌区域性化疗增效作用观察[J].2010,(1).
- [2]陈丽萍,迟宝荣.超声引导下微波凝固治疗肝癌的应用进展[J].2005,(2).
- [3]国虹,刘卫东,董桂兰,等.分子靶向药物索拉非尼不良反应的防治[J].2010,(5).
- [4]辛红.肝癌患者超声引导下微波凝固治疗前后免疫指标的动态变化[J].2001,(2).
- [5]徐立,黎鹏,林小军,等.索拉非尼单药治疗晚期肝细胞癌的临床观察[J].2009,(1).
- [6]周业庭,黎瑞,吴柏华,等.复发性肝癌的外科综合治疗--附136例临床治疗体会[J].2007,(22).
- [7]全毅,刘建刚,蔡悦成,等.经肝动脉化疗栓塞联合肿瘤间质治疗肝癌后免疫功能改变[J].2009,(11).
- [8]王志军,王茂强.TACE联合分子靶向药物治疗原发性肝癌的研究进展[J].2009,(4).
- [9]张岚,任正刚,干育红,等.索拉非尼治疗不能手术的原发性肝细胞癌的疗效及预后因素[J].2010,(8).
- [10]Ryoo BY,Moon DB,Yoon DH,etc.Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.[J].2010,40(8).
- [11]Wiedmann MW,Mossner J.Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies.[J].2011,11(6).
- [12]Chen CL,Naib T.Sorafenib-associated multivessel coronary artery vasospasm.[J].2011,36(4).
- [13]Giantonio BJ,Jenab-Wolcott J.Bevacizumab: current indications and future development for management of solid tumors.[J].2009,9(4).
- [14]Guan DX,Zhu YQ,Wang HY,etc.Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.[J].2011,53(2).